Adaptimmune Ltd.

121 articles with Adaptimmune Ltd.

• Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

  5/19/2021

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.

• Adaptimmune Reports First Quarter Financial Results and Business Update

  5/6/2021

  - Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1 - - Astellas nominates second target as part of allogeneic co-development and co-commercialization agreement - - Financial guidance confirmed: funded into early 2023 -

• Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

  4/27/2021

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy meeting.

• Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

  4/22/2021

  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US markets open on Thursday, May 6, 2021. Following the announcement, the Company will host a live teleconference and webcast at 9:00 a.m. EDT (2:00 p.m. BST) that same day (details below).

• Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

  2/25/2021

  - Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric junction, and melanoma cancers confirming potential of SPEAR T-cells for solid tumors - -

• Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

  11/9/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented data from the dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer Conference.

• Adaptimmune Reports Q3 Financial Results and Business Update

  11/5/2020

  - Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial to be presented at CTOS - - Virtual Investor Day planned for November 20, 2020 - - Financial guidance confirmed: funded into 2022 -

• Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

  10/15/2020

  Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” by the Society for the Immunotherapy of Cancer (“SITC”) Conference

• Adaptimmune Reports Q2 Financial Results and Business Update

  8/6/2020

  - Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma - - Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022

• Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

  7/22/2020

  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The press release and the live webcast of the con

• Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares - June 04, 2020

  6/4/2020

  PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to p

• Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares - June 02, 2020

  6/2/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares at a price to the public of $11.00 per ADS.

• Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares - Jun 01, 2020

  6/1/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that it intends to offer and sell 12,500,000 American Depositary Shares in an underwritten public offering.

• Adaptimmune Reports Q1 Financial Results

  5/14/2020

  - Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations - - Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kin

• SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

  5/12/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented advances from its “off-the-shelf” or allogeneic platform at the American Society for Gene and Cell Therapy Annual meeting which kicked off in virtual format.

• 

  BioSpace Global Roundup, April 30

  4/30/2020

  Biopharma companies from across the globe provide updates on their business and pipelines.

• Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

  4/29/2020

  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before the U.S. markets open on Thursday, May 14, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The pres

• Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

  4/28/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s Committee for Orphan Medicinal Products has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.

• Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

  2/27/2020

  - Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -

• Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

  2/20/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S. markets open on Thursday, February 27, 2020.